---
layout: post
title: "恒瑞医药：尼莫地平口服溶液获得药品注册证书"
date: 2022-01-24 17:16:20 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600276" data-code="600276|1|1" data-code2="600276|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600276&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600276_0" data-code="K 600276|1|1" data-code2="K 600276|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>恒瑞医药公告，尼莫地平口服溶液获得药品注册证书。尼莫地平口服溶液适用于颅内囊性动脉瘤破裂的蛛网膜下腔出血(SAH)成人患者。子公司药品阿得贝利单抗注射液上市许可申请获受理。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201242259137425>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)